Breast cancer (early) - docetaxel

Docetaxel for the adjuvant treatment of early node-positive breast cancer

Summary

Docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer.

Update to guidance

CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal.   NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.

Guidance documents

• Guidance PDF format  | MS Word format
• Quick reference guide PDF format
• Understanding NICE guidance PDF format  | MS Word format

Implementing this guidance

• Costing template
• Audit criteria

• How this guidance was produced
• Background information